Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams. / Ciofu, O; Giwercman, B; Walter-Rasmussen, J; Pressler, T; Pedersen, S S; Høiby, N.

In: Journal of Antimicrobial Chemotherapy, Vol. 35, No. 2, 1995, p. 295-304.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ciofu, O, Giwercman, B, Walter-Rasmussen, J, Pressler, T, Pedersen, SS & Høiby, N 1995, 'Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.', Journal of Antimicrobial Chemotherapy, vol. 35, no. 2, pp. 295-304.

APA

Ciofu, O., Giwercman, B., Walter-Rasmussen, J., Pressler, T., Pedersen, S. S., & Høiby, N. (1995). Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams. Journal of Antimicrobial Chemotherapy, 35(2), 295-304.

Vancouver

Ciofu O, Giwercman B, Walter-Rasmussen J, Pressler T, Pedersen SS, Høiby N. Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams. Journal of Antimicrobial Chemotherapy. 1995;35(2):295-304.

Author

Ciofu, O ; Giwercman, B ; Walter-Rasmussen, J ; Pressler, T ; Pedersen, S S ; Høiby, N. / Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams. In: Journal of Antimicrobial Chemotherapy. 1995 ; Vol. 35, No. 2. pp. 295-304.

Bibtex

@article{b7890400ba2111ddae57000ea68e967b,
title = "Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.",
abstract = "Chromosomal beta-lactamase production is considered to be the most important resistance mechanism of Pseudomonas aeruginosa against beta-lactams. Recently we have detected serum and sputum antibodies against P. aeruginosa chromosomal beta-lactamase (a beta ab), using immunoblotting techniques. In this study we have developed an enzyme-linked-immunosorbent assay to measure serum a beta ab response in 124 cystic fibrosis patients in a cross-sectional study and in 54 cystic fibrosis patients in a longitudinal study. The a beta ab response occurred after a median of 3 years following onset of chronic infection and was significantly higher (P < 0.0002) in patients chronically infected with resistant strains than in those from whom resistant strains were occasionally isolated. The a beta ab levels correlated (r = 0.51, P = 0.0001) with the number of beta-lactam courses. A 14 fold increase in a beta ab levels occurred during the 14 year period covered by the longitudinal study. The results of this study show that a beta ab to P. aeruginosa is a specific marker for resistance development of P. aeruginosa to beta-lactams.",
author = "O Ciofu and B Giwercman and J Walter-Rasmussen and T Pressler and Pedersen, {S S} and N H{\o}iby",
note = "Keywords: Adolescent; Adult; Antibodies, Bacterial; Biological Markers; Child; Child, Preschool; Chromosomes, Bacterial; Cross-Sectional Studies; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Infant; Longitudinal Studies; Middle Aged; Pseudomonas Infections; Pseudomonas aeruginosa; Reproducibility of Results; Sensitivity and Specificity; beta-Lactamases; beta-Lactams",
year = "1995",
language = "English",
volume = "35",
pages = "295--304",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.

AU - Ciofu, O

AU - Giwercman, B

AU - Walter-Rasmussen, J

AU - Pressler, T

AU - Pedersen, S S

AU - Høiby, N

N1 - Keywords: Adolescent; Adult; Antibodies, Bacterial; Biological Markers; Child; Child, Preschool; Chromosomes, Bacterial; Cross-Sectional Studies; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Infant; Longitudinal Studies; Middle Aged; Pseudomonas Infections; Pseudomonas aeruginosa; Reproducibility of Results; Sensitivity and Specificity; beta-Lactamases; beta-Lactams

PY - 1995

Y1 - 1995

N2 - Chromosomal beta-lactamase production is considered to be the most important resistance mechanism of Pseudomonas aeruginosa against beta-lactams. Recently we have detected serum and sputum antibodies against P. aeruginosa chromosomal beta-lactamase (a beta ab), using immunoblotting techniques. In this study we have developed an enzyme-linked-immunosorbent assay to measure serum a beta ab response in 124 cystic fibrosis patients in a cross-sectional study and in 54 cystic fibrosis patients in a longitudinal study. The a beta ab response occurred after a median of 3 years following onset of chronic infection and was significantly higher (P < 0.0002) in patients chronically infected with resistant strains than in those from whom resistant strains were occasionally isolated. The a beta ab levels correlated (r = 0.51, P = 0.0001) with the number of beta-lactam courses. A 14 fold increase in a beta ab levels occurred during the 14 year period covered by the longitudinal study. The results of this study show that a beta ab to P. aeruginosa is a specific marker for resistance development of P. aeruginosa to beta-lactams.

AB - Chromosomal beta-lactamase production is considered to be the most important resistance mechanism of Pseudomonas aeruginosa against beta-lactams. Recently we have detected serum and sputum antibodies against P. aeruginosa chromosomal beta-lactamase (a beta ab), using immunoblotting techniques. In this study we have developed an enzyme-linked-immunosorbent assay to measure serum a beta ab response in 124 cystic fibrosis patients in a cross-sectional study and in 54 cystic fibrosis patients in a longitudinal study. The a beta ab response occurred after a median of 3 years following onset of chronic infection and was significantly higher (P < 0.0002) in patients chronically infected with resistant strains than in those from whom resistant strains were occasionally isolated. The a beta ab levels correlated (r = 0.51, P = 0.0001) with the number of beta-lactam courses. A 14 fold increase in a beta ab levels occurred during the 14 year period covered by the longitudinal study. The results of this study show that a beta ab to P. aeruginosa is a specific marker for resistance development of P. aeruginosa to beta-lactams.

M3 - Journal article

C2 - 7759393

VL - 35

SP - 295

EP - 304

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -

ID: 8745125